BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Christiansen D, Earnest-Silveira L, Chua B, Meuleman P, Boo I, Grubor-Bauk B, Jackson DC, Keck ZY, Foung SKH, Drummer HE, Gowans EJ, Torresi J. Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine. Sci Rep. 2018;8:6483. [PMID: 29691437 DOI: 10.1038/s41598-018-24762-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Lin T, Chi X, Liu X, Pan S, Chen W, Duan H, Zhang X, Yang W. Recombinant Full-Length Hepatitis C Virus E1E2 Dimer Elicits Pangenotypic Neutralizing Antibodies. Front Immunol 2022;13:831285. [DOI: 10.3389/fimmu.2022.831285] [Reference Citation Analysis]
2 Liu T, Li L, Cheng C, He B, Jiang T. Emerging prospects of protein/peptide-based nanoassemblies for drug delivery and vaccine development. Nano Res . [DOI: 10.1007/s12274-022-4385-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Yato K, Matsuda M, Watanabe N, Watashi K, Aizaki H, Kato T, Tamura K, Wakita T, Muramatsu M, Suzuki R. Induction of neutralizing antibodies against hepatitis C virus by a subviral particle-based DNA vaccine. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105266] [Reference Citation Analysis]
4 Bankwitz D, Krey T, Pietschmann T. [Development approaches for vaccines against hepatitis C virus infections]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2022. [PMID: 35015104 DOI: 10.1007/s00103-021-03477-9] [Reference Citation Analysis]
5 Manne V, Ryan J, Wong J, Vengayil G, Basit SA, Gish RG. Hepatitis C Vaccination: Where We Are and Where We Need to Be. Pathogens 2021;10:1619. [PMID: 34959574 DOI: 10.3390/pathogens10121619] [Reference Citation Analysis]
6 Zhu M, Yang H, Lu Y, Yang H, Tang Y, Li L, Zhu Y, Yuan J. Cardiac ectopic lymphoid follicle formation in viral myocarditis involving the regulation of podoplanin in Th17 cell differentiation. FASEB J 2021;35:e21975. [PMID: 34618980 DOI: 10.1096/fj.202101050RR] [Reference Citation Analysis]
7 Pisano MB, Giadans CG, Flichman DM, Ré VE, Preciado MV, Valva P. Viral hepatitis update: Progress and perspectives . World J Gastroenterol 2021; 27(26): 4018-4044 [PMID: 34326611 DOI: 10.3748/wjg.v27.i26.4018] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
8 Andrianov AK, Fuerst TR. Immunopotentiating and Delivery Systems for HCV Vaccines. Viruses 2021;13:981. [PMID: 34070543 DOI: 10.3390/v13060981] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Schlotthauer F, McGregor J, Drummer HE. To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity. Viruses 2021;13:805. [PMID: 33946211 DOI: 10.3390/v13050805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Elliott T, Cooke GS, Garvey L. Interventions to reduce acute hepatitis C virus in HIV-positive MSM. Curr Opin Infect Dis 2020;33:1-9. [PMID: 31789696 DOI: 10.1097/QCO.0000000000000614] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Kardani K, Basimi P, Fekri M, Bolhassani A. Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development. Expert Rev Clin Pharmacol 2020;13:1001-46. [PMID: 32838584 DOI: 10.1080/17512433.2020.1814743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sepulveda-Crespo D, Resino S, Martinez I. Hepatitis C virus vaccine design: focus on the humoral immune response. J Biomed Sci 2020;27:78. [PMID: 32631318 DOI: 10.1186/s12929-020-00669-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Duncan JD, Urbanowicz RA, Tarr AW, Ball JK. Hepatitis C Virus Vaccine: Challenges and Prospects. Vaccines (Basel) 2020;8:E90. [PMID: 32079254 DOI: 10.3390/vaccines8010090] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
14 Cox AL. Challenges and Promise of a Hepatitis C Virus Vaccine. Cold Spring Harb Perspect Med 2020;10:a036947. [PMID: 31548228 DOI: 10.1101/cshperspect.a036947] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
15 Houghton M. Hepatitis C Virus: 30 Years after Its Discovery. Cold Spring Harb Perspect Med. 2019;9. [PMID: 31501269 DOI: 10.1101/cshperspect.a037069] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Filskov J, Andersen P, Agger EM, Bukh J. HCV p7 as a novel vaccine-target inducing multifunctional CD4+ and CD8+ T-cells targeting liver cells expressing the viral antigen. Sci Rep 2019;9:14085. [PMID: 31575882 DOI: 10.1038/s41598-019-50365-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
17 Wong SH, Jassey A, Wang JY, Wang WC, Liu CH, Lin LT. Virus-Like Particle Systems for Vaccine Development against Viruses in the Flaviviridae Family. Vaccines (Basel) 2019;7:E123. [PMID: 31547131 DOI: 10.3390/vaccines7040123] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
18 Christiansen D, Earnest-Silveira L, Grubor-Bauk B, Wijesundara DK, Boo I, Ramsland PA, Vincan E, Drummer HE, Gowans EJ, Torresi J. Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery. Sci Rep 2019;9:9251. [PMID: 31239471 DOI: 10.1038/s41598-019-45461-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
19 Collett S, Torresi J, Earnest-silveira L, Christiansen D, Elbourne A, Ramsland PA. Probing and pressing surfaces of hepatitis C virus-like particles. Journal of Colloid and Interface Science 2019;545:259-68. [DOI: 10.1016/j.jcis.2019.03.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
20 Dominguez-Molina B, Machmach K, Perales C, Tarancon-Diez L, Gallego I, Sheldon JL, Leal M, Domingo E, Ruiz-Mateos E. Toll-Like Receptor 7 (TLR-7) and TLR-9 Agonists Improve Hepatitis C Virus Replication and Infectivity Inhibition by Plasmacytoid Dendritic Cells. J Virol 2018;92:e01219-18. [PMID: 30232187 DOI: 10.1128/JVI.01219-18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
21 Bailey JR, Barnes E, Cox AL. Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. Gastroenterology. 2019;156:418-430. [PMID: 30268785 DOI: 10.1053/j.gastro.2018.08.060] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 18.3] [Reference Citation Analysis]